GRAIL (GRAL) Shares Climb +65.8% Over 30 Days Following Positive FDA Panel Vote
Key Takeaways
- GRAIL shares surged roughly 65.8% over the trailing 30 days, climbing from about $80 to a closing price of $132.63.
- The rally was driven primarily by a positive U.S. FDA advisory committee vote on the Galleri multi-cancer early detection test.
- The stock has gained approximately 94% over the past quarter, extending a sustained upward trend.
- Several analysts raised their price targets after the panel vote, with one firm lifting its target to $150.
- GRAIL remains unprofitable on a net basis, and the FDA's final premarket approval decision is still pending.
GRAIL's Focus on Early Cancer Detection
GRAIL, Inc. (GRAL) is a commercial-stage healthcare company centered on detecting cancer early, when treatment options are most effective. Its main product, the Galleri multi-cancer early detection (MCED) test, relies on a simple blood draw to screen for more than 50 types of cancer, including several without current recommended screenings. The test uses a targeted methylation-based platform that incorporates next-generation sequencing, large-scale clinical studies, and machine learning.
Based in Menlo Park, California, GRAIL was spun off from genomics company Illumina (ILMN) and has about 900 employees. The company posted roughly $165 million in trailing-twelve-month revenue but still operates at a net loss. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track the name closely because a successful FDA approval for Galleri could unlock a substantial and still largely untapped market for blood-based cancer screening.
Recent Stock Performance: 30 Days and the Quarter
Over the last 30 days, GRAL shares moved from a closing price near $80 on August 28 to $132.63 on September 28, for a gain of roughly 65.8%. The advance carried the stock toward the upper end of its 52-week range of $41.50 to $134.42 and came with a noticeable increase in trading volume.
The quarterly view shows even stronger results. From a closing level around $68 at the end of June, the stock advanced approximately 94% over the three-month period. The path was not entirely smooth; shares dipped briefly into the low-$60s in early August before the late-quarter catalyst produced a clear breakout.
The Catalyst Behind the 30-Day Move
The main driver was a favorable vote by the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on the premarket approval (PMA) application for Galleri. The panel voted 7-2 in support of the test's benefits, representing a key step in the regulatory process and lifting expectations for eventual approval.
That outcome prompted several analyst updates. Canaccord Genuity raised its price target to $150 from $80 while keeping a Buy rating, Mizuho increased its target to $100 from $65 with a Neutral rating, and TD Cowen raised its estimated approval probability to 95%. The combination of the positive panel result, higher targets, and heavier volume propelled the stock from around $80 to above $130 in a short span.
Drivers of the Quarterly Advance
The three-month gain reflects ongoing regulatory progress more than any isolated event. GRAIL filed its PMA application for Galleri with the FDA in January 2026, backed by data from the PATHFINDER 2 registrational study and the NHS-Galleri trial. Throughout the quarter, investors gradually adjusted the stock's valuation as the advisory committee meeting neared and as additional clinical and commercial milestones supported the approval case.
The company also continued to expand commercially, with full-year 2025 revenue rising roughly 17% year over year, and presented at several investor conferences. This steady buildup of regulatory and operational developments, capped by the September panel vote, supported the sustained upward move.
Key Items to Monitor Going Forward
The most immediate catalyst remains the FDA's final decision on the Galleri PMA application, expected in the coming months. Approval could validate the MCED market and aid commercial growth, whereas a delay or negative outcome would likely pressure the stock.
Investors should also watch GRAIL's next quarterly earnings report, anticipated around November 11, 2026, for updates on revenue growth, cash burn, reimbursement progress, and Galleri adoption. Broader competitive moves in cancer screening, macroeconomic factors affecting high-beta healthcare names, and any additional analyst changes will also play a role. As with all volatile equities, near-term price swings can be sizable. From what I see, I’m watching this closely for how the next regulatory milestone unfolds.
Reviewing AI Trading Approaches
In my own research on names like this, I sometimes look at Tickeron’s AI Trading Bots to explore automated strategies that align with my risk parameters and time horizons. These tools provide a range of options across different market conditions, which can complement traditional analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for GRAL turns positive, indicating new upward trend
GRAL saw its Momentum Indicator move above the 0 level on September 18, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator turned positive. In 40 of the 41 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GRAL just turned positive on September 21, 2026. Looking at past instances where GRAL's MACD turned positive, the stock continued to rise in 18 of 20 cases over the following month. The odds of a continued upward trend are 90%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in 107 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 97 of 104 cases where GRAL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
GRAL broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GRAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.330) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (18.248) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement